Last reviewed · How we verify
NCT06090630
MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer
EARLY_PHASE1 trial testing Diffusion Weighted Imaging in Benign Breast Neoplasm in 83 participants. Completed in 3 February 2023.
3 February 2023
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 83 |
| Start date | 31 July 2017 |
| Primary completion | 3 February 2023 |
| Estimated completion | 3 February 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Diffusion Weighted Imaging
- Magnetic Resonance Spectroscopic Imaging
Conditions studied
- Benign Breast Neoplasm — all drugs for Benign Breast Neoplasm →
- Breast Carcinoma — all drugs for Breast Carcinoma →
- Malignant Breast Neoplasm — all drugs for Malignant Breast Neoplasm →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
Adults 18 to 80, female only, with Benign Breast Neoplasm or Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies how well an imaging technique called magnetic resonance (MR) spectroscopic imaging works in identifying breast cancer in women with benign or suspicious areas in the breast. Magnetic resonance imaging (MRI) is a diagnostic tool used to investigate the location of tumors in different organs. Since radiological pictures do not have sufficient information for tumor grades, invasive procedure such as biopsy is performed on patients with breast cancers for diagnosis. Breast tissue contains water, fat, and chemicals known as metabolites. MR spectroscopic imaging may help to characterize the various breast metabolite steady state levels and identify the differences between necrosis and tumor recurrence, which is difficult using radiological procedures such as MRI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06090630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Diffusion Weighted Imaging
Trials testing the same drug.
- NCT04796818 — An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cance · NA · recruiting
- NCT02390635 — PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed A · Phase 1 · recruiting
- NCT02590497 — Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery · NA · withdrawn
- NCT02359565 — Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrin · Phase 1 · active not recruiting
- NCT02020720 — 18F-DOPA-PET in Planning Surgery in Patients With Gliomas · EARLY_PHASE1 · completed
Other recruiting trials for Benign Breast Neoplasm
Currently open trials in the same condition.
- NCT07465523 — A Novel Approach in the Evaluation of Breast Masses With Doppler US · recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06090630 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06090630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing